|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 75.02 USD | -0.19% |
|
+0.08% | +0.71% |
| 01-06 | Noul Co., Ltd. Unveils AI-Automated Cervical Cancer Diagnostics Solution at CES 2026 | CI |
| 01-06 | Evercore ISI Downgrades Hologic to In Line From Outperform, Adjusts PT to $78 From $79 | MT |
| Capitalization | 16.75B 14.43B 13.46B 12.52B 23.27B 1,513B 25.01B 154B 60.75B 725B 62.83B 61.53B 2,658B | P/E ratio 2026 * |
21.6x | P/E ratio 2027 * | 18.7x |
|---|---|---|---|---|---|
| Enterprise value | 16.33B 14.07B 13.12B 12.21B 22.68B 1,475B 24.38B 151B 59.22B 707B 61.24B 59.98B 2,591B | EV / Sales 2026 * |
3.81x | EV / Sales 2027 * | 3.44x |
| Free-Float |
74.01% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Hologic, Inc.
| 1 day | -0.19% | ||
| 1 week | +0.08% | ||
| Current month | +0.71% | ||
| 1 month | +0.03% | ||
| 3 months | +13.80% | ||
| 6 months | +16.09% | ||
| Current year | +0.71% |
| 1 week | 74.79 | 75.17 | |
| 1 month | 74.19 | 75.19 | |
| Current year | 74.49 | 75.17 | |
| 1 year | 51.9 | 75.34 | |
| 3 years | 51.9 | 87.88 | |
| 5 years | 51.9 | 87.88 | |
| 10 years | 26.49 | 87.88 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 62 | 2013-12-06 | |
Karleen Oberton
DFI | Director of Finance/CFO | 56 | 2018-07-31 |
Essex Mitchell
COO | Chief Operating Officer | 46 | 2023-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 55 | 2011-10-31 | |
| Chairman | 62 | 2015-06-15 | |
| Director/Board Member | 71 | 2017-05-14 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.19% | +0.08% | +6.87% | -6.17% | 16.75B | ||
| +0.45% | +1.22% | +12.15% | +6.99% | 234B | ||
| -0.99% | -8.60% | +0.46% | +109.09% | 194B | ||
| +0.82% | +1.83% | +0.96% | -12.33% | 168B | ||
| -3.96% | -8.74% | -5.88% | +93.49% | 139B | ||
| -0.53% | +1.06% | -8.34% | -6.06% | 61.18B | ||
| +1.67% | -0.40% | +18.93% | +7.89% | 48.22B | ||
| -0.75% | -2.02% | +0.98% | -7.70% | 41.37B | ||
| -3.27% | -3.79% | -1.93% | +26.08% | 38.86B | ||
| +0.46% | +5.03% | +13.93% | +19.53% | 37.8B | ||
| Average | -0.56% | -0.83% | +3.81% | +23.08% | 97.87B | |
| Weighted average by Cap. | -0.47% | -1.77% | +3.35% | +35.80% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 4.28B 3.69B 3.44B 3.2B 5.95B 387B 6.4B 39.49B 15.53B 185B 16.07B 15.73B 680B | 4.51B 3.89B 3.62B 3.37B 6.27B 407B 6.74B 41.58B 16.36B 195B 16.92B 16.57B 716B |
| Net income | 776M 669M 624M 580M 1.08B 70.12B 1.16B 7.16B 2.82B 33.59B 2.91B 2.85B 123B | 889M 766M 714M 664M 1.23B 80.25B 1.33B 8.19B 3.22B 38.45B 3.33B 3.26B 141B |
| Net Debt | -423M -365M -340M -316M -588M -38.22B -632M -3.9B -1.53B -18.31B -1.59B -1.55B -67.13B | -1.24B -1.07B -994M -925M -1.72B -112B -1.85B -11.4B -4.49B -53.53B -4.64B -4.54B -196B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-01-15 | 75.02 $ | -0.19% | 2,359,982 |
| 26-01-14 | 75.16 $ | +0.39% | 3,490,689 |
| 26-01-13 | 74.87 $ | +0.01% | 1,511,656 |
| 26-01-12 | 74.86 $ | -0.01% | 1,516,409 |
| 26-01-09 | 74.87 $ | -0.01% | 1,898,890 |
Delayed Quote Nasdaq, January 15, 2026 at 04:00 pm
More quotesTrader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.

Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- HOLX Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
















